Osage Partners related stories
All articles and analysis
LunaPBC attracts $4.6 mlnLa Jolla, California-based LunaPBC, a provider of a genomic and health data platform, has raised $4.6 million in funding. The investors included ARCH Venture Partners, Bain Capital Ventures, F-Prime Capital, Illumina Ventures and Osage University Partners.
- Arrakis Therapeutics rakes in $75 mln Series B
Waltham, Massachusetts-based Arrakis Therapeutics, a biopharmaceutical company, has raised $75 million in Series B funding. VenBio Partners and Nextech Invest led the round with participation from Omega Funds, HBM Healthcare Investments, GV, WuXi AppTec Venture Fund, Alexandria Venture Investments, Canaan Partners, Advent Life Sciences, Pfizer Ventures, Celgene Corporation, Osage University Partners and the estate of Henri Termeer.
Osage Partners raises $273mThe Pennsylvania venture capital firm closes its third life sciences fund.
- Osage University Partners raises $273 mln for third fund
Osage University Partners has closed its third fund at $273 million, beating its $250 million target. The Bala Cynwyd, Pennsylvania-based venture firm invests in startups that commercialize university research.
- VC-backed SiFive hires business development VP
SiFive, a Silicon Valley-based provider of commercial RISC-V processor IP and silicon solutions, has appointed Hiren Majmudar vice president of business development. Previously, he led Intel Capital's corporate development practice for silicon and IP. SiFive is backed by Sutter Hill Ventures, Spark Capital, Osage University Partners, Chengwei, Huami, SK Hynix, Intel Capital and Western Digital.
- KenSci takes in $22 mln Series B
Seattle-based KenSci, a machine learning and artificial intelligence-powered risk prediction platform for healthcare, has raised $22 million in Series B funding. Polaris Partners led the round with participation from Ignition Partners, Osage University Partners, Mindset Ventures and UL Ventures.
- Ribon Therapeutics lands $65 mln Series B
Lexington, Massachusetts-based Ribon Therapeutics, a biotechnology company, has raised $65 million in Series B financing. Novartis Venture Fund led the round with participation from JJDC, Celgene Corporation, The Column Group, Deerfield Management, U.S. Venture Partners, Osage University Partners, Takeda Ventures and Euclidean Capital.